



## News Release

### **Cougar Biotechnology to Present at SoCalBio Investor Conference**

**Los Angeles, CA, March 23, 2006** – Cougar Biotechnology, Inc, a privately held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the 8<sup>th</sup> SoCalBio Investor Conference that will take place on March 29<sup>th</sup>-30<sup>th</sup> at the Wilshire Grand Hotel in downtown Los Angeles. This conference is organized by the Southern California Biomedical Council as a forum for facilitating the interaction between life-science entrepreneurs, investors, other members of the financial community, and senior representatives from the healthcare industry.

#### **About Cougar Biotechnology**

Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase I clinical trial in prostate cancer, CB3304, which is currently in a Phase I trial in non-Hodgkin's lymphoma and CB1089, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at [www.cougarbiotechnology.com](http://www.cougarbiotechnology.com).

#### **Contacts:**

Alan H. Auerbach, Cougar Biotechnology, Inc.  
+1 310 443 4209